TIL Stock Forecast: Instil Bio, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$5.23
−5.77% on the day

The median 12-month analyst price target for Instil Bio, Inc. is $7. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 48 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$37.6M
Ticker Nerd rank
48/ 100
Median analyst target
$7.00
Analysts covering
1
Revenue$0.0
Operating income−$5.4M
Net income−$4.3M
Free cash flow−$4.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−14.0%
1M
−12.0%
YTD
−52.5%
1Y
−56.3%
From 52W high
−60.2%
From 52W low
0.0%
$5
$13
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Instil Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
48/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
85
Accruals
70
Quality
60
Issuance
47
Value
47
Volatility
36
Revisions
26
Momentum
10

Growth (85): Sales and profits are climbing, and climbing faster than before.

Momentum (10): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

TIL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TIL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$4$6$8$10$12$14Jan 26Apr 26Jul 26Oct 26TILHigh $7.00Median $7.00Low $7.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
0
Buy
1
Hold
0
Sell
$7.00
Low
$7.00
Median
$7.00
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
7 Jan 2026HC Wainwright & Co.DowngradeNeutral—
11 Sept 2025HC Wainwright & Co.ReiteratesBuy—
27 Aug 2025HC Wainwright & Co.ReiteratesBuy—
15 Aug 2025HC Wainwright & Co.ReiteratesBuy—
5 June 2025HC Wainwright & Co.ReiteratesBuy—
2 June 2025JMP SecuritiesReiteratesMarket Perform—
23 May 2025HC Wainwright & Co.MaintainsBuy—
22 May 2025HC Wainwright & Co.MaintainsBuy—
5 Mar 2025HC Wainwright & Co.ReiteratesBuy—
13 Feb 2025JMP SecuritiesReiteratesMarket Perform—
7 Jan 2025JefferiesUpgradeBuy—
18 Nov 2024HC Wainwright & Co.ReiteratesBuy—
14 Nov 2024HC Wainwright & Co.MaintainsBuy—
4 Nov 2024JMP SecuritiesInitiatesMarket Perform—
17 Sept 2024HC Wainwright & Co.ReiteratesBuy—
16 Sept 2024BairdReiteratesOutperform—
16 Sept 2024HC Wainwright & Co.MaintainsBuy—
13 Sept 2024BairdMaintainsOutperform—
12 Sept 2024HC Wainwright & Co.MaintainsBuy—
23 Aug 2024HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for TIL.

Market Radar

This page is one stock. Monday covers all of them.

TIL appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

TIL vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Instil Bio, Inc. returned −56.3% against +6.9% for the S&P 500, dividends included.

TIL vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26TILS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TIL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
0.3×

Cheaper than 91% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−25.3%

Higher than 30% of US stocks

Return on assets
−10.8%

Higher than 26% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Instil Bio, Inc. has a market value of $37.6M and an enterprise value of $56.7M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$30.3M.

  • Free cash flow in the twelve months to 30 June 2026: −$33.6M.

  • Shares outstanding: 6.8M.

  • Instil Bio, Inc. employs 17 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

TIL and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TILInstil Bio, Inc.$37.6M48
GRCEGrace Therapeutics, Inc.$36.0M44
CUECue Biopharma, Inc.$34.7M20
PLRXPliant Therapeutics, Inc.$36.8M68
CNTBConnect Biopharma Holdings Ltd.$37.1M45
VERUVeru, Inc.$33.1M51
ATNMActinium Pharmaceuticals, Inc.$32.9M87

Take a look at TIL’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Instil Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about TIL

What is the TIL stock price forecast for 2026-2027?

The median 12-month analyst price target for Instil Bio, Inc. is $7. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TIL stock a buy right now?

Of the 1 analyst covering Instil Bio, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Instil Bio, Inc. 48 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TIL?

As at 21 Nov 2026, Instil Bio, Inc. ranks 48 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (85 of 100).

Will TIL stock go up?

No one can know that. What the data says: the median 12-month target from 1 analyst is $7, and Ticker Nerd's factor model ranks Instil Bio, Inc. 48 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TIL stock forecast for 2030?

No analyst covering Instil Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TIL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $7 over the next 12 months.

How has TIL stock performed over the past year?

Instil Bio, Inc. returned -56.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Instil Bio, Inc. do?

Instil Bio Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer. The company’s current work centers on tumor-infiltrating lymphocyte, or TIL, cell therapies designed to harness a patient’s own immune cells to attack solid tumors.

Company

About Instil Bio, Inc.

Instil Bio Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer. The company’s current work centers on tumor-infiltrating lymphocyte, or TIL, cell therapies designed to harness a patient’s own immune cells to attack solid tumors. Its pipeline also includes next-generation programs built around engineered TIL approaches and bispecific antibody candidates aimed at difficult-to-treat cancers. Instil Bio Inc. operates as a research-driven biotechnology business, combining cell therapy development, manufacturing expertise, and clinical-stage oncology programs to address areas of significant unmet medical need. Headquartered in Dallas, Texas, the company plays a specialized role in the oncology market through its focus on advanced immunotherapy platforms and novel therapeutic candidates.

CEO Mr. Bronson Crouch · 17 employees · United States · https://instilbio.com